secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001551152-23-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie reports FY 2022 adjusted EPS $13.77 (+16.4% YoY); guides FY 2023 adjusted EPS $10.70-$11.10
--------------------------------------------------------------------------------

- FY 2022 net revenues $58.054B (+3.3% reported, +5.1% operational); Q4 net revenues $15.121B (+1.6% reported, +3.8% operational).
- GAAP diluted EPS FY $6.63 (+2.8%); adjusted diluted EPS $13.77 (+16.4%). Q4 GAAP diluted EPS $1.38 (-38.9%); adjusted $3.60 (+16.9%).
- Immunology portfolio FY net revenues $28.924B (+14.4%); Humira $21.237B, Skyrizi $5.165B, Rinvoq $2.522B.
- Hematologic oncology portfolio FY net revenues $6.577B (-9.0%); Imbruvica $4.568B, Venclexta $2.009B.
- 2023 adjusted diluted EPS guidance $10.70-$11.10 (excludes IPR&D and milestones); management cites U.S. Humira LOE as headwind.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/0001551152-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/abbv-20230209.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer